万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>遗传学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>肿瘤学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生3>>医学(研究与实验)
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生3>>生物工程与应用微生物

CANCER GENE THERAPY《癌症基因治疗》 (官网投稿)

简介
  • 期刊简称CANCER GENE THER
  • 参考译名《癌症基因治疗》
  • 核心类别 SCIE(2023版), 外文期刊,
  • IF影响因子
  • 自引率1.50%
  • 主要研究方向医学-BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物;GENETICS & HEREDITY 遗传学;MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验;ONCOLOGY 肿瘤学

主要研究方向:

等待设置主要研究方向
医学-BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物;GENETICS & HEREDITY 遗传学;MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验;ONCOLOGY 肿瘤学

CANCER GENE THERAPY《癌症基因治疗》(月刊). Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and&nbs...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:https://www.nature.com/cgt/

3、投稿网址:

https://mts-cgt.nature.com/cgi-bin/main.plex

4、官网邮箱:CancerGeneTherapy@us.nature.com

5、官网电话:+44 (0)20 3192 2216

6、期刊刊期:月刊,一年出版十二期。

2021522日星期六

                             

 

投稿须知【官网信息】

 

Guide to Authors

ABOUT THE JOURNAL

Aims and Scope

Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.

Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

Journal Details Editor-in-Chief: Georgios Giamas, UK Editorial office: Springer Nature, 4 Crinan Street, London, UK, CancerGeneTherapy@us.nature.com

Frequency: 12 issues a year

ARTICLE TYPE SPECIFICATIONS

ARTICLE DESCRIPTION

SPECIFICATION

Article

These reports of original research should follow the structure outlined below, and should include a clear statement of purpose, a description of the procedures, methods, and subjects or materials used, and a full report of the findings, including discussion, and references to relevant findings of other researchers

Unstructured abstract max 200 words

Main body of text (excluding references, figures/tables) not to exceed 12,000 words;

Max 7 tables or figures;

Max 60 References

Review Article Review articles in Cancer Gene Therapy aim to provide accessible, authoritative overviews of a field or topic. Reviews should communicate a sense of enthusiasm, weaving background information with the latest advances, and placing both of these elements in the context of the rest of the field. The abstract describes what the article is about in a succinct, easily digestible way. It should not contain specialist details, abbreviations, references or figure citations. References should concentrate on significant original research papers

Unstructured abstract max 200 words

Main body of text (excluding abstract, references, figures/tables) not to exceed 4,000 words

Max 7 tables or figures;

Max 120 references

Brief Communication

A Brief Communication reports a concise study of high quality and broad interest. Shorter descriptions of important, innovative developments will be considered for preliminary publication.

Unstructured abstract max 200 words

Main body of text should be no more than 2 pages

Max one table or figure

Max 10 references

Perspective

Perspectives are a hybrid between a correspondence and a review, providing an opinion-driven perspective on a particular research topic or field of interest to Cancer Gene Therapy readership. Authors should present a (provocative) view that can be supported by data and literature with the goal of sparking debate and stimulating future research avenues.

No abstract required

Main body of text (excluding abstract, references, figures/tables) not to exceed 2,000 words;

Max 4 tables or figures

Max 25 references

Correspondence

Denotes short, arresting, and timely comments on material published in the journal (including right-of-reply) as well as anything of likely interest to the readers, such as policy debates and community announcements

No abstract required

PREPARATION OF ARTICLES

House Style: Authors should adhere to the following formatting guidelines:

Text should be double spaced with a wide margin.

All pages and lines are to be numbered.

Do not make rules thinner than 1px (0.36mm).

Use a coarse hatching pattern rather than shading for tints in graphs.

Colour should be distinct when being used as an identifying tool.

Commas, not spaces should be used to separate thousands.

At first mention of a manufacturer, the town (and state if USA) and country should be provided.

Statistical methods: For normally distributed data, mean (SD) is the preferred summary statistic. Relative risks should be expressed as odds ratios with 95% confidence interval. To compare two methods for measuring a variable the method of Bland & Altman (1986, Lancet 1, 307–310) should be used; for this, calculation of P only is not appropriate.

Units: Use metric units (SI units) as fully as possible. Preferably give measurements of energy in kiloJoules or MegaJoules with kilocalories in parentheses (1 kcal = 4.186kJ). Use % throughout.

Abbreviations: On first using an abbreviation place it in parentheses after the full item. Very common abbreviations such as FFA, RNA, need not be defined. Note these abbreviations: gram g; litre l; milligram mg; kilogram kg; kilojoule kJ; megajoule MJ; weight wt; seconds s; minutes min; hours h. Do not add s for plural units.

Please note that Articles must contain the following components. Please see below for further details.

Cover letter

Title page (excluding acknowledgements)

Abstract

Introduction

Materials (or Subjects) and Methods

Results

Discussion (including Conclusion)

Acknowledgements

Conflict of Interest

References

Figure legends

Tables

Figures

Cover Letter Authors should provide a cover letter that includes the affiliation and contact information for the corresponding author. Authors should briefly discuss the importance of the work and explain why it is considered appropriate for the diverse readership of the journal. The cover letter should confirm the material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration. If the manuscript has been previously considered for publication in another journal, please include the previous reviewer comments, to help expedite the decision by the Editorial team.

The cover letter must be on headed notepaper and include the corresponding author’s signature. Please also include a statement confirming that more than one author has directly accessed and verified the data reported in the manuscript.

Title Page

The title page must contain:

Title of the paper - brief, informative, of 150 characters or less and should not make a statement or conclusion

Full names of all the authors and their affiliations, together with the e-mail address of the corresponding author. If authors regard it as essential to indicate that two or more co-authors are equal in status, they may be identified by an asterisk symbol with the caption ‘These authors contributed equally to this work’ immediately under the address list.

All authors should provide an institutional email address, this is especially important for the corresponding author and the paper will not proceed through peer review if an institutional email address isn’t provided on the paper and within the submission system, unless there is a legitimate reason why the corresponding author cannot provide one.

……

更多详情:

https://www.nature.com/cgt/authors-and-referees/gta


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭